Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05326087 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 1, 2026 to Dec 1, 2027
    • Start date: Dec 1, 2025 to Jun 1, 2026
    • Study completion date: Dec 1, 2027 to Dec 1, 2028
    v5
  2. Primary completion date: Dec 1, 2025 to Dec 1, 2026
    • Start date: Dec 1, 2024 to Dec 1, 2025
    • Study completion date: Dec 1, 2026 to Dec 1, 2027
    v4
  3. Start date: Dec 1, 2023 to Dec 1, 2024v3
  4. Primary completion date: Dec 1, 2024 to Dec 1, 2025
    • Start date: Dec 1, 2022 to Dec 1, 2023
    • Study completion date: Dec 1, 2025 to Dec 1, 2026
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. PPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger. The primary outcome is the euploidy rate of blastocysts.
Trial Details
NCT Number NCT05326087
Lead Sponsor ShangHai Ji Ai Genetics & IVF Institute
Conditions
(from sponsor)		 Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation, Polycystic Ovarian Syndrome, GnRH Antagonist
Related terms Polycystic Ovary Syndrome
Enrollment 204 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov